Incyte Reverset Program Delayed 12-18 Months For Confirmatory Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's refusal to green-light Phase III study plans for Incyte's Reverset HIV therapy could delay market launch by at least a year, according to the company